395 related articles for article (PubMed ID: 33540334)
1. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
Reddy DS; Kongot M; Kumar A
Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
[TBL] [Abstract][Full Text] [Related]
2. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
4. A Review on Coumarin Derivatives as Potent Anti-tuberculosis Agents.
Mujeeb S; Singh K; Yogi B; Ansari V; Sinha S
Mini Rev Med Chem; 2022; 22(7):1064-1080. PubMed ID: 34579635
[TBL] [Abstract][Full Text] [Related]
5. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.
Horita Y; Takii T; Yagi T; Ogawa K; Fujiwara N; Inagaki E; Kremer L; Sato Y; Kuroishi R; Lee Y; Makino T; Mizukami H; Hasegawa T; Yamamoto R; Onozaki K
Antimicrob Agents Chemother; 2012 Aug; 56(8):4140-5. PubMed ID: 22615274
[TBL] [Abstract][Full Text] [Related]
9. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
Rajkhowa S; Deka RC
Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
[TBL] [Abstract][Full Text] [Related]
10. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
[TBL] [Abstract][Full Text] [Related]
11. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
Sheikh BA; Bhat BA; Mehraj U; Mir W; Hamadani S; Mir MA
Curr Pharm Biotechnol; 2021; 22(4):480-500. PubMed ID: 32600226
[TBL] [Abstract][Full Text] [Related]
12. Current Insights into the Chemistry and Antitubercular Potential of Benzimidazole and Imidazole Derivatives.
Parwani D; Bhattacharya S; Rathore A; Mallick C; Asati V; Agarwal S; Rajoriya V; Das R; Kashaw SK
Mini Rev Med Chem; 2021; 21(5):643-657. PubMed ID: 33138762
[TBL] [Abstract][Full Text] [Related]
13. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
14. Drug Resistance Characteristics of
Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
[No Abstract] [Full Text] [Related]
15. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
16. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
Martins M
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
18. It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
Amaral L
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):76. PubMed ID: 21796848
[No Abstract] [Full Text] [Related]
19. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
